Israeli firm to develop nanoscale enzyme therapy

Nov. 24, 2003 — BioDelivery Sciences International Inc. (BDSI) is creating an Israeli subsidiary to develop nanoscale drug-delivery therapies to treat one of many inherited diseases caused by an enzyme deficiency.


Biorazyme Ltd., the tentative name for the new company co-owned by Newark, N.J.-based BDSI and Israeli joint venture partners, will develop new oral enzyme replacement formulations for Gaucher Disease. The company said the new therapy could reduce costs and dosage of current intravenous therapies.


BDSI’s Bioral delivery technology uses nanocrystalline delivery vehicles made from all-natural components that wrap around the enzyme and allow it to be delivered into the body, according to a company news release.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.